{"id":678991,"date":"2023-11-30T09:48:02","date_gmt":"2023-11-30T09:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=678991"},"modified":"2023-11-30T09:48:02","modified_gmt":"2023-11-30T09:48:02","slug":"diabetic-macular-edema-market-anticipating-remarkable-growth-by-2032-insights-by-delveinsight-adverum-allergan-allergo-allgenesis-ascentage-asclepix-celltrion-exonate-novartis-kalvista","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-macular-edema-market-anticipating-remarkable-growth-by-2032-insights-by-delveinsight-adverum-allergan-allergo-allgenesis-ascentage-asclepix-celltrion-exonate-novartis-kalvista_678991.html","title":{"rendered":"Diabetic Macular Edema Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Adverum, Allergan, Allergo, Allgenesis, Ascentage, AsclepiX, Celltrion, Exonate, Novartis, KalVista"},"content":{"rendered":"
\n
\"Diabetic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Diabetic Macular Edema market size in the 7MM is expected to change during the study period 2019\u20132032, at a CAGR of 3.2%. In 2020, according to DelveInsight\u2019s estimates, the highest market size of Diabetic Macular Edema is accessed in the United States followed by Germany, and Japan.<\/div>\n

DelveInsight’s “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Macular Edema market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Diabetic Macular Edema drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Diabetic Macular Edema treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Diabetic Macular Edema: An Overview<\/strong><\/p>\n

Diabetic Macular Edema (DME) is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in developed and other developing countries. Common signs and symptoms include dark spots like a smudge on glasses or gaps that may appear in the vision, blurred vision, double vision, colors can fade, or the affected person may find bright light or glare difficult.<\/p>\n

All people with Type 1 or Type 2 diabetes are at risk for DR and DME. The risk of developing DR or DME increases significantly the longer a person has diabetes. The American Academy of Ophthalmology (AAO) estimates that nearly 80% of patients with Type 1 diabetes will have developed DR after living with diabetes for 15 years. There is a 50% chance that patients with Type 2 diabetes will develop DR after living with diabetes for around 20 years.<\/p>\n

Diabetic Macular Edema diagnosis is clinically performed by fundoscopy; when the center of the macula (fovea centralis) is thickened or swollen, this is referred to as clinically significant central-involved macular edema (CI-CSME). It is referred to as a clinically significant non-central-involved macular edema (NCI-CSME) when it is unaffected.<\/p>\n

Diabetic Macular Edema Market Key Facts<\/strong><\/p>\n